Feed RZLT
RZ

Rezolute, Inc.

RZLT · NASDAQ

$4.22 -0.24% (-$0.01)
1M -8.26%
Market Cap $401.5M
P/E Ratio -
Div. Yield -
ROE 58.82%

Bulios Fair Price

$2.74

35.1% downside

Trenutna cena

$4.22

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RZLT trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
59 /100
Fair
P/B 3.44x
P/E N/A
P/FFO N/A
Growth
39 /100
Stable
Book val. growth 2.75%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 73.68%
Asset turnover 0.00x
ROE 58.82%
Debt
100 /100
Low
Debt/Equity 0.01x
Current ratio 15.84x
Int. coverage N/A
Stability
56 /100
Moderate
Beta 0.61x
Profitable years 0
EPS volatility 44.80%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RZLT
Online

O podjetju

Rezolute, Inc. (RZLT) is a biotechnology company specializing in the development of therapeutics to improve the lives of patients suffering from metabolic disorders and endocrine disorders. Headquartered in the United States, the company focuses on researching and developing new treatment approaches and therapies for patients with type 1 diabetes and other health issues. The company concentrates on innovations in pharmacology and therapeutic methods, working to create new drugs that can enhance the quality of life for affected patients. Shares of Rezolute, Inc. (RZLT) can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Nevan Charles Elam

Employees

68

Headquarters

Redwood City

Prihajajoči dogodki

16 SEP.

Earnings

Upcoming earnings report

3d
05 NOV.

Earnings

Upcoming earnings report

53d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.